T5224, a selective inhibitor of AP-1, was first developed to treat rheumatoid arthritis by blocking c-Fos/AP-1-mediated inflammatory and matrix metalloproteinase (MMP) action and has successfully advanced into phase II clinical trials [40]. Here, FOS is linked to rheumatoid arthritis.